CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 64 enrolled
Drug / intervention
IL5 Antagonist or anti-IL5R-antibody or Omalizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04158050
NCT04158050N/ACompleted
CompareCT.gov

Comparison of Biologicals in Treatment of Severe Asthma - Real Life Experiences

Helsinki University Central Hospital·observational·Posted Nov 8, 2019·Updated Dec 4, 2023

In Brief

An observational study evaluating IL5 Antagonist or anti-IL5R-antibody or Omalizumab for Asthma. Completed, enrolled 64 participants across 1 site.

Detailed Summary

This is a retrospective clinical study on adult patients (18 years or more) with biological therapy for severe asthma at the Helsinki University Central Hospital (HUCH). This is a real-life study with a broader patient population than in a randomized controlled trial. Omalizumab has been used for treatment of asthma in HUCH since January 2009, anti-IL5 therapies starting with mepolizumab since April 2016.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesFinland
CollaboratorsIda Montini Foundation

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 8, 2019
Enrollment StartJan 1, 2018
Primary CompletionOct 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.6 years ago

Interventions

IL5 Antagonist or anti-IL5R-antibody or Omalizumabdrug

mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma